Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azosemide is a small molecule loop diuretic of the monosulfamyl class, used primarily to treat hypertension, edema (including cardiac and renal edema), ascites, and fluid overload conditions such as those associated with congestive heart failure, liver disease, and nephrotic syndrome. It acts mainly by inhibiting sodium and chloride reabsorption in both the medullary and cortical segments of the thick ascending limb of the loop of Henle in the kidney. This results in increased excretion of water, sodium, chloride, and other electrolytes. The exact molecular mechanism is not fully understood but is similar to that of furosemide; however, intravenous azosemide has a significantly greater diuretic effect than furosemide due to less first-pass metabolism. Oral bioavailability is low (~20%), with peak plasma concentrations reached within 3–4 hours after administration. The drug exhibits high protein binding (>95%) and has a terminal half-life of about 2–3 hours[1][2][5][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azosemide.